USPTO Patent Application: Anti-DPP3 Antibody Formulations
Summary
The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.
What changed
This document is a publication of a United States patent application (US20260083672A1) filed by 4TEEN4 Pharmaceuticals GmbH. The application pertains to novel formulations and specific dosage amounts for administering an anti-DPP3 antibody or a fragment thereof to human patients. The stated purpose includes the treatment of severe medical conditions, specifically life-threatening circulatory failure conditions like shock.
As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property rights and advancements in the development of therapeutic antibodies. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in antibody development or the treatment of shock and circulatory failure, should be aware of this filing as it may impact their research and development strategies or competitive landscape.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS
Application US20260083672A1 Kind: A1 Mar 26, 2026
Assignee
4TEEN4 Pharmaceuticals GmbH
Inventors
Andreas Bergmann, Karine Bourgeois
Abstract
The present inventions are directed to formulations and dosage amounts for the administration of a humanized anti-DPP3 antibody or fragment thereof to humans, including for the treatment of life-threatening circulatory failure conditions, such as shock.
CPC Classifications
A61K 9/08 A61K 9/0019 A61K 47/20 A61K 47/22 A61K 47/26 C07K 16/40 A61K 2039/505 A61K 2039/545 C07K 2317/24 C07K 2317/76 C07K 2317/92
Filing Date
2025-08-26
Application No.
19310528
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.